Amyloidosis-related nephropathy Medical Services in China

Amyloidosis-related nephropathy is a progressive kidney disorder caused by the extracellular deposition of misfolded amyloid proteins—primarily immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, tubulointerstitium, and vasculature of the kidneys. These insoluble fibrillar aggregates disrupt normal renal architecture and function, leading to proteinuria (often nephrotic-range), declining glomerular filtration rate (GFR), hypertension, edema, and ultimately end-stage kidney disease (ESKD) if untreated. Pathogenesis hinges on systemic protein misfolding: in AL amyloidosis, clonal plasma cell dyscrasia produces abnormal light chains that aggregate into β-pleated sheets resistant to proteolysis; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid. Renal involvement occurs in ~70% of AL amyloidosis cases and up to 90% of AA cases with longstanding inflammation. Epidemiologically, AL amyloidosis has an incidence of 8–12 per million person-years globally, with median age at diagnosis of 65 years; AA amyloidosis is rarer in high-income countries but more prevalent in regions with endemic chronic infections or autoinflammatory disorders. Risk factors include advanced age (>60), monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic inflammatory or infectious diseases, and certain genetic variants (e.g., SAA1 polymorphisms in AA). Early symptoms are often subtle—fatigue, foamy urine, weight gain from edema—but rapidly progress to hypoalbuminemia, hyperlipidemia, acute kidney injury, and thromboembolic complications due to loss of antithrombin and other plasma proteins. Quality of life is profoundly impaired: patients experience physical debilitation from fluid overload and malnutrition, psychological distress from diagnostic uncertainty and treatment toxicity, social isolation due to fatigue and dialysis dependence, and significant financial burden from prolonged monitoring and multidisciplinary care. Without timely intervention, median survival after renal involvement onset is <2 years in untreated AL amyloidosis. Accurate diagnosis requires kidney biopsy with Congo red staining and immunohistochemistry or mass spectrometry-based typing—critical because therapeutic strategies differ fundamentally between AL and AA subtypes. Early referral to specialized nephrology centers with amyloidosis expertise is essential to optimize outcomes.

Amyloidosis-related nephropathy is a progressive renal complication arising from the systemic deposition of misfolded amyloid fibrils—most commonly immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, interstitium, and vasculature of the kidneys. This leads to proteinuria, declining glomerular filtration rate (GFR), hypertension, and ultimately end-stage kidney disease (ESKD) if untreated. Management requires a multidisciplinary approach coordinated by nephrologists, hematologists (for AL), rheumatologists (for AA), and pathologists, with early diagnosis via renal biopsy and Congo red staining with apple-green birefringence under polarized light being essential.

Conservative treatment forms the cornerstone of supportive care and aims to mitigate complications while preserving residual renal function. Strict blood pressure control—targeting <130/80 mmHg—is achieved using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), which reduce intraglomerular pressure and attenuate proteinuria. Sodium restriction (<2 g/day) and fluid management are critical to control edema and prevent volume overload, particularly in patients with nephrotic-range proteinuria (>3.5 g/day). Hyperlipidemia is managed with high-intensity statins (e.g., atorvastatin 40–80 mg daily), given the elevated cardiovascular risk. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to avoid catabolism without exacerbating glomerular hyperfiltration; excessive protein restriction is discouraged. Anemia is addressed with erythropoiesis-stimulating agents (ESAs) and iron supplementation only when ferritin >100 ng/mL and transferrin saturation >20%, avoiding overcorrection. Diuretic therapy (e.g., furosemide plus spironolactone) must be titrated carefully to prevent acute kidney injury or electrolyte derangements. Regular monitoring of serum creatinine, cystatin C–based eGFR, 24-hour urine protein, albumin-to-creatinine ratio (ACR), and cardiac biomarkers (NT-proBNP, troponin) is mandatory for timely intervention.

Pharmacotherapy targets the underlying amyloidogenic process. In AL amyloidosis, first-line therapy is hematologic-directed: daratumumab-based regimens (e.g., daratumumab + cyclophosphamide + dexamethasone [D-CD]) have demonstrated superior hematologic response rates (≥60% very good partial response or better) and improved renal outcomes versus traditional melphalan-dexamethasone. Bortezomib-containing regimens (e.g., CyBorD) remain effective, especially in patients with cardiac involvement. Autologous stem cell transplantation (ASCT) is considered for eligible patients (age <70 years, preserved cardiac function, adequate organ reserve), offering potential deep hematologic remission and renal stabilization. For AA amyloidosis, treatment focuses on suppressing the chronic inflammatory driver—e.g., biologics such as tocilizumab (IL-6 inhibitor) in refractory rheumatoid arthritis or canakinumab (IL-1β inhibitor) in familial Mediterranean fever—thereby reducing SAA production and halting amyloid deposition. Colchicine remains first-line for FMF-associated AA. Novel agents under investigation include NEOD001 (anti-amyloid antibody, though development halted) and CAEL-101 (monoclonal antibody targeting misfolded light chains), currently in Phase III trials.

Surgical treatment is limited but pivotal in select scenarios. Kidney transplantation is feasible in AL amyloidosis only after achieving sustained hematologic remission (≥6 months with negative free light chain ratio and absence of clonal plasma cells on bone marrow biopsy), as recurrence risk is high without disease control. Graft survival at 5 years approaches 75–80% in rigorously selected patients. Combined heart-kidney transplantation may be indicated in AL with concurrent severe cardiac amyloidosis. For AA amyloidosis, transplantation carries lower recurrence risk if inflammation is controlled, and 10-year graft survival exceeds 60%. Surgical debulking is not applicable; however, splenectomy has historical relevance in hereditary amyloidosis (e.g., ATTRv) but no role in AL or AA nephropathy.

China offers distinct advantages in the management of amyloidosis-related nephropathy. First, rapid diagnostic integration is facilitated by nationwide access to advanced renal pathology services—including laser microdissection coupled with mass spectrometry (LMD-MS)—which enables precise amyloid typing in >95% of cases within 7–10 days, surpassing many Western centers in turnaround time. Second, China’s centralized drug approval pathway has accelerated access to novel therapies: daratumumab received NMPA approval for AL amyloidosis in 2022, and biosimilar rituximab and bortezomib are widely available at significantly reduced cost. Third, large-scale clinical registries (e.g., the China Amyloidosis Registry, launched in 2021) support real-world evidence generation and protocol standardization across >120 tertiary nephrology centers. Fourth, integrated Traditional Chinese Medicine (TCM) adjuncts—such as Huangqi decoction (Astragalus membranaceus-based formulas)—are used under evidence-informed protocols to ameliorate proteinuria and fatigue, with randomized trials demonstrating additive antiproteinuric effects when combined with ACEi. Finally, China’s tiered healthcare system ensures seamless referral from community hospitals to national centers (e.g., Peking University First Hospital, Shanghai Renji Hospital), enabling timely initiation of complex regimens.

Recovery and long-term follow-up require structured patient engagement. Patients should undergo quarterly nephrology visits for renal function assessment, biannual hematologic evaluation (serum free light chains, bone marrow studies if indicated), and annual cardiac imaging (echocardiography, cardiac MRI). Vaccination against pneumococcus, influenza, and SARS-CoV-2 is strongly recommended due to immunosuppression-related infection risk. Physical activity should be individualized: aerobic exercise (e.g., brisk walking 30 min/day, 5×/week) improves endothelial function and reduces cardiovascular mortality, but heavy resistance training is discouraged in active nephrotic syndrome. Psychosocial support—including counseling and peer-led support groups hosted by the Chinese Society of Nephrology—is integral, given the high prevalence of depression and treatment-related distress. Smoking cessation and strict alcohol abstinence are non-negotiable. Dietary adherence is reinforced through registered dietitian consultations, emphasizing potassium and phosphorus restriction only upon progression to CKD Stage 4–5. Finally, patients must be educated on early symptom recognition—sudden weight gain (>2 kg/3 days), dyspnea, orthostatic dizziness, or foamy urine—and instructed to seek urgent evaluation to prevent irreversible decompensation. With comprehensive, individualized care, many patients achieve prolonged renal stability and meaningful quality-of-life preservation.